

a rapid i.v. injection during the first 3 and last 3 days of RT and three more cycles of the same CT with FU and LV (group A, 111 patients) or pelvic RT with concomitant FU alone (group B, 109 patients).

**Results:** As of August 1998, after a median follow-up of 4.9 years, there was no significant difference in either 3-year DFS (group A, 70.3%; group B, 68.2%,  $p = 0.53$ ) or OS (group A, 77%; group B, 73.3%,  $p = 0.75$ ). The incidence of severe side effects was significantly higher in patients of group A than of those of group B (32.4% vs 4.6%,  $p < 0.0001$ ).

**Conclusion:** The incorporation of additional CT with FU and LV to postoperative concomitant RT and bolus infusion of FU does not offer a 3-year survival benefit over concomitant RT and bolus infusion of FU and increases significantly toxicity in patients with stage II or III rectal cancer.

213

## POSTER DISCUSSION

### A randomized phase II trial assessing Irinotecan (IRI) and 5FU/folinic acid (LV), "Mayo regimen", in first line palliative chemotherapy patients (pts) with metastatic colorectal cancer (MCRC)

C. Pozzo, S. Pyrhönen, I. Bodrogi, J. Szanto, H. Kamica-Mlodkowska, H. Starkammar, J. Izso, P. Hansen, M. Kjaer, N. Noël, G. Gruia, C. Barone. *Università Sacro Cuore, Roma, Italy; Helsinki University Hospital, Helsinki, Finland; St Magrit Hospital, Budapest, Hungary; PCK Memorial Hospital, Gdynia-Redlowo, United Kingdom; University Hospital, Linköping, Sweden; BM Hospital, Budapest, Hungary; Arhus Komune hospital, Arhus; Aalborg hospital, Aalborg, Denmark; Rhône-Poulenc Rorer, Antony, France*

Single agent IRI is active in MCRC with significant survival advantage over BSC or best 5FU schedule in pts with prior 5FU failure (The Lancet, 31 Oct. 1998). In this randomized phase II, pts were assigned to either (A) IRI at 350 mg/m<sup>2</sup> day (d) 1 q 3 w or (B) LV 20 mg/m<sup>2</sup> I.V. bolus/day (d) + 5FU 425 mg/m<sup>2</sup> as IV bolus/d, d1-d5, repeated every 4 weeks (wks). 159 pts (82 in A and 77 in B) were randomized; 136 pts are treated, eligible and evaluable (65 in A, 71 in B). Tumor assessments were done q 3 cycles (cy) for A arm and q 2 cy for B. After progression pts were crossed-over provided PS  $\leq 2$  with good renal, liver and hematological functions. Response were reviewed by independent experts (ERRC). The main pts characteristics are comparable between groups A and B: median age 62 vs 58, primary colon/rectum (%) 64/36 vs 57/43, PS 0 53% vs 62% ( $p = 0.24$ ), number of organs  $\geq 2$  44% vs 46%, respectively. A high proportion of pts had synchronous metastasis: 68% in A, 61 in B. Results before cross-over are: 1. Response rate per ERRC in A: 15.4% [95% CI: 7.6–26.5] and in B: 9.9% [95% CI: 4.1–19.3]. 2. TTP in A: 6.4 months (m) [range: 0.7–11.6+], B: 3.9 m [range: 1.2–9.8] ( $p = 0.03$ ) 3. Duration of response and stabilization: A: 7.0 m [range: 1.3–11.5+], B: 5.6 m [range: 1.4–9.8] ( $p = 0.015$ ). Results after cross-over and survival will be presented at the meeting. The main NCI grade 3/4 adverse were as expected: neutropenia 41% vs 42%, diarrhea 25% vs 9%, vomiting 9% vs 7% in A and B respectively.

**Conclusion:** This randomized trial suggests that IRI, single agent, is at least as active as LV/5FU "Mayo regimen" in first line MCRC pts.

214

## POSTER

### A pilot study of a feasibility and economic analysis of home based chemotherapy in advanced colorectal cancer

S. Ingleby<sup>1</sup>, J. Barnwell<sup>1</sup>, J. Baker<sup>2</sup>, P. Harvey<sup>2</sup>, D.J. Kerr<sup>1</sup>, V. Law<sup>3</sup>, A. Young<sup>1</sup>. <sup>1</sup>University of Birmingham, Cancer Research Campaign Trials Unit, Birmingham; <sup>2</sup>Queen Elizabeth Hospital, Birmingham; <sup>3</sup>ZenecaPharma, Alderley, United Kingdom

In the UK, there has been a shift in care towards home or community based treatment following recent changes in Government healthcare policy. This is a pilot study of home chemotherapy for patients with advanced colorectal cancer. The aims are to: 1) quantify the costs of homebased chemotherapy; 2) measure the patient and carer acceptability of this; 3) establish a local home chemotherapy treatment/liaison service.

**Method:** one senior oncology research nurse was responsible for the treatment and assessment of the patient, with backup from medical staff as required. Eligible patients receiving intravenous regimens of Lokich 5FU (continuous), DeGramont 5FU and Folinic Acid (48 hour) and Tomudex(c) were invited onto study to receive home management for the first 12 weeks of treatment. Patients and their carers were administered acceptability questionnaires before treatment, midway and after treatment was completed – their enthusiasm, worry, coping/supporting ability, with regard to home treatment, were scored on an ordinal scale. The costs of travel/phone, nurse time and central venous line costs for DeGramont patients were recorded, to compare against hospital based treatment.

**Results:** early analysis suggests that enthusiasm was high; patients have low or decreasing worry; patients coped well and carers gave good support.

In analysing the costs of 22 patients entered onto study, an average cost per week per regimen was calculated, and compared with an average cost per week of hospital based care, as shown below:

Hospital: DeGramont-£230.00; Lokich-£92.00; Tomudex-£35.39 Vs. Home £143.67; £46.95; £40.85

We conclude that home managed chemotherapy is acceptable, cost effective and preferred by patients. Following this pilot study, further study on a national scale is being instigated to look at the value of home based chemotherapy.

(Tomudex(c) is a product of Zeneca Pharmaceuticals)

215

## POSTER

### Thymidylate synthase (TS) protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil (5FU)

S. Cascinu, C. Aschele, S. Barni, D. Debernardis, C. Baldo, G. Tunesi, V. Catalano, P. Giordani, A.M. Baldelli, G. Catalano. *Department of Medical Oncology, Pesaro, Italy*

**Purpose:** Aims of the present study is to test whether the correlation between TS expression and the clinical response is still valid for a bolus 5FU regimen, and to compare TS levels between liver metastases and abdominal recurrences from colon cancer.

**Methods:** 41 patients (M/F 25/16, median age 60 years) with unresectable metastatic or recurrent colon cancer, treated homogeneously with bolus 5FU and leucovorin

**Results:** 27 patients (66%) showed high levels of TS expression as defined by a TS score equal to 3 and 4. The proportion of cases with high levels of TS expression was significantly higher in abdominal recurrences (18 of 22, 82%) compared to liver metastases (9 out of 19, 47%;  $p = 0.02$ ). Intratumoral TS protein expression was inversely correlated with response to chemotherapy (response rate: 7/14, 50%, versus 0/27, in patients with low and high levels of TS expression, respectively;  $p = 0.0001$ ).

**Conclusions:** These results confirm that the level of TS protein expression predicts for response to 5FU, even with a bolus schedule. The higher TS levels observed in abdominal compared to liver metastases may account for their different responsiveness to 5FU chemotherapy.

216

## POSTER

### Prospective study of adjuvant therapy with monoclonal antibody 17-1A of Dukes' B2/B3-colon carcinoma – Interim analysis of toxicity

W. Queisser, A. Franz, G. Hartung, J. Sturm, L. Edler, D. Bornbusch, G. Dietrich, Ch. Böllinger, M. Gonnemann, C. Wojatschek. *Onkologisches Zentrum, III. Med. Klinik, Universitätsklinikum, D-68167 Mannheim, Georgia*

**Purpose:** Adjuvant immune therapy with the murine monoclonal antibody (mAb) 17-1A has been shown to be an alternative to chemotherapy in the treatment of stage In colorectal cancer presenting similar efficacy in combination with lower toxicity. Therefore we suggested that also patients with Dukes' B colon cancer could have benefit from adjuvant treatment with mAb 17-1A.

**Patients and Methods:** In 1997 we started this prospective multicentre trial including patients after curative (RO) resection of Dukes' stage B2/B3 adenocarcinoma of the colon. Patients are randomly assigned to either treatment with mAb 17-1A (arm A) or observation regimen (arm B). In the treatment arm patients are administered 500 mg of mAb 17-1A intravenously followed by four infusions of 100 mg every four weeks. So far, 214 patients (114 arm A/100 arm B) have been entered into the trial.

**Results:** Our interim data concerning toxicity reveal that of 267 courses of mAb 17-1A eligible we saw a total number of 58 (22%) adverse events. Except one case of severe toxicity (exacerbation of Wegener's granulomatosis) all side effects are of WHO grades 1–2 (17% grade 1, 5% grade 2). Adverse events are most frequent within the first course with 39% events (versus 22% in course 2, 17% in course 3, 20% in course 4, 2% in course 5). Diarrhoea, nausea and vomiting represented the most common side effects.

**Conclusions:** These data underline the favourable toxicity profile of adjuvant treatment with mAb 17-1A, which might confirm its role in the therapy of the a priori good risk group of patients with Dukes B colon carcinoma.